A small company that is all about the development of dermatology drugs has snagged a new investor and will soon start on a manufacturing facility that will catapult it into the CDMO market.
Tergus Pharma says an investment from private equity investor Great Point Partners will allow it to build its first commercial manufacturing facility. The Durham, North Carolina-based company currently provides topical formulation development, in vitro permeating testing, clinical trial materials and other services.
“For years we have discussed building a commercial facility. The equity capital from GPP will enable us to do this,” Tergus CEO Vijendra Nalamothu said in a statement.
Construction of the 100,000 square foot operation is slated to begin next month and to be complete in 2020, the company said. Terms of the deal were not disclosed.
The investment comes as the dermatology market is undergoing big changes. Nestle last month announced it is in exclusive talks to sell its skin health unit for about $10.1 billion to a consortium led by private equity EQT Partners. That comes just five years after the Swiss company moved deeper into the skin products to diversify away from slower sales in food.
The investors will pick up prescription brands including acne topical treatment Epiduo, as well as aesthetic and consumer products. About 5,000 employees also are expected to move.
Novartis is in the process of selling its Sandoz U.S. dermatology business, a dermatology development center and about 300 generics to India’s Aurobindo Pharma. Bayer in 2018 offloaded its prescription dermatology portfolio to Dutch company LEO Pharma.
By Eric Palmer
Source: Fierce Pharma
The agreement, signed last month, includes an upfront payment of $1bn and $400m in regulatory milestone payments. The acquisition introduces AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, into GSK’s pipeline.
Vertex Pharmaceuticals and CRISPR Therapeutics have scored another regulatory approval for Casgevy (exagamglogene autotemcel) after the European Commission granted conditional marketing authorisation to the gene therapy.
US biopharmaceutical company Gilead Sciences is to acquire CymaBay Therapeutics for $4.3 billion. Gilead offered to purchase all outstanding shares of CymaBay for $32.50 per share in cash. CymaBay, based in the US near San Francisco, California, has developed the investigational drug seladelpar, which is currently in clinical Phase 3.